GSK621: AMPK Agonist for Metabolic Pathway and Leukemia Research

Executive Summary: GSK621 is a selective and potent agonist of AMP-activated protein kinase (AMPK), a key regulator of cellular energy homeostasis (APExBIO). It activates AMPK at IC50 values between 13–30 µM in multiple cell lines, promoting downstream phosphorylation of acetyl-CoA carboxylase (ACC) at S79 and ULK1 at S555. In acute myeloid leukemia (AML) models, GSK621 robustly induces AMPKα T172 phosphorylation and apoptosis (Xiao et al., 2024). In vivo, GSK621 reduces leukemia growth and extends survival in murine xenograft models at 30 mg/kg twice daily. GSK621 is insoluble in water/ethanol but soluble in DMSO (≥28.5 mg/mL), and is intended for research use only.

Biological Rationale

AMP-activated protein kinase (AMPK) is a heterotrimeric serine/threonine kinase that acts as a central sensor of cellular energy status. It orchestrates metabolic adaptations by modulating pathways involved in fatty acid synthesis, glycolysis, autophagy, and protein synthesis (Xiao et al., 2024). Dysregulation of AMPK signaling is implicated in metabolic disorders and cancer progression. In tumor-associated macrophages (TAMs), AMPK activation reprograms immunosuppressive phenotypes and enhances anti-tumor immunity. Small-molecule AMPK activators like GSK621 provide researchers with tools to dissect these pathways in vitro and in vivo.

Mechanism of Action of GSK621

GSK621 is a cell-permeable, highly specific AMPK agonist. It binds to the kinase complex and directly promotes AMPK activation, increasing phosphorylation at threonine 172 (T172) on the α subunit. This results in downstream phosphorylation of target substrates:

• Acetyl-CoA carboxylase (ACC) at serine 79 (S79): inactivates ACC, suppressing fatty acid biosynthesis.
• ULK1 at serine 555 (S555): promotes autophagy initiation.

Activation of AMPK by GSK621 leads to the inhibition of mammalian target of rapamycin complex 1 (mTORC1), which downregulates protein synthesis and cell proliferation. In AML models, GSK621 triggers apoptosis via sustained AMPK activation and downstream metabolic stress (APExBIO).

Evidence & Benchmarks

• GSK621 activates AMPK in various cell lines with IC50 values between 13–30 µM under standard culture conditions (APExBIO).
• Robust phosphorylation of AMPKα (T172) and ACC (S79) is observed upon GSK621 treatment in AML cell lines (Xiao et al., 2024).
• GSK621 induces apoptosis in acute myeloid leukemia cells, both in established lines and primary patient samples (Xiao et al., 2024).
• In murine MOLM-14 xenograft models, intraperitoneal administration of GSK621 (30 mg/kg, twice daily) results in significant reduction of leukemia burden and increased survival, with enhanced AMPK and ACC phosphorylation in tumor tissues (APExBIO).
• GSK621 suppresses mTORC1-dependent protein synthesis, promotes autophagy, fatty acid oxidation, and glucose uptake in metabolic assays (Xiao et al., 2024).

For additional context, see this article on actionable workflows for GSK621; the current review extends the focus to quantitative in vivo benchmarks and solubility parameters.

Applications, Limits & Misconceptions

GSK621 is widely used as an AMP-activated protein kinase activator in the following research contexts:

• Dissecting metabolic pathway regulation in cell and animal models.
• Acute myeloid leukemia (AML) research, especially for studies of apoptosis induction and metabolic stress.
• Investigating autophagy, fatty acid oxidation, and glycolytic flux.
• Modeling mTORC1 inhibition and its downstream effects.
• Immunometabolic modulation in cancer microenvironment studies.

For broader methodological context, the article here describes precision applications in tumor microenvironment models; the current review clarifies quantitative solubility and in vivo efficacy parameters for GSK621.

Common Pitfalls or Misconceptions

• GSK621 is not soluble in water or ethanol. It must be dissolved in DMSO (≥28.5 mg/mL), with warming or ultrasonication as needed (APExBIO).
• Intended for research use only: GSK621 is not approved for diagnostic or medical applications.
• AMPK activation does not universally induce cytotoxicity: Cellular response depends on lineage and context.
• Stock solutions require cold storage: Below −20°C for stability over several months.
• GSK621 specificity: While highly selective for AMPK, off-target effects at high concentrations cannot be excluded without controls.

For troubleshooting in metabolic pathway assays, see this article; the current review provides more detailed in vivo AML application data and regulatory notes.

Workflow Integration & Parameters

GSK621 is supplied as a crystalline solid by APExBIO (SKU: B6020). For in vitro studies, prepare fresh DMSO stock solutions at ≥28.5 mg/mL, warming to 37 °C or using an ultrasonic bath if needed. For animal models, intraperitoneal dosing of 30 mg/kg twice daily has been validated in leukemia xenograft models. Store dry powder at 2–8 °C and stock solutions below −20 °C. Dosing, timing, and buffer composition should be optimized for each experimental system, and DMSO controls are essential for specificity. For product specifications and ordering, visit the GSK621 product page.

Conclusion & Outlook

GSK621 is a robust, selective AMPK agonist that empowers advanced studies of metabolic signaling, apoptosis, and immunometabolic reprogramming, particularly in acute myeloid leukemia and cancer models. Its validated performance in both cell-based and in vivo systems, alongside well-defined solubility and storage parameters, make it a preferred tool for metabolic pathway research. Ongoing studies will further clarify its translational potential and boundaries in immunometabolism and therapeutic research.